Dr Robert Gabbay: Diabetes Clinical Trials Should Be More Inclusive

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains why clinical trials need to be inclusive and how the Health Equity Now initiative is working to recruit more diverse populations with diabetes.

The Health Equity Now initiative is working to make clinical trials more inclusive, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.

Transcript

The new ADA and EASD Type 1 Diabetes Guidance mentions that most data are from White European populations. What is being done to improve data collection from other groups?

One of the important aspects of our Health Equity Now is to think about, how can we ensure that clinical trials are broadly representative of the population, and particularly people who were at greatest risk for complications in the development of diabetes. So we're working to make available clinical trial opportunities for individuals and, particularly on the advocacy perspective, advocating for more inclusive recruitment of individuals for studies related to diabetes treatments.